ELVN-001 is named as an intervention in 2 current clinical trials in our UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Canada, South Korea, Australia, Israel and Japan registers. 2 are recruiting patients now. All registered phases are Phase 1. The lead sponsor is Enliven Therapeutics. The most-studied condition is Chronic Myeloid Leukemia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377 · ClinicalTrials.gov ↗ · Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
|
Phase 1 | Recruiting | Enliven Therapeutics | UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Canada, South Korea, Australia, Israel |
|
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
NCT06787144 · ClinicalTrials.gov ↗ · CML (Chronic Myelogenous Leukemia), Chronic Phase CML
|
Phase 1 | Recruiting | Enliven Therapeutics | Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Enliven Therapeutics | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Canada, South Korea, Australia, Israel and Japan registers name ELVN-001 as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Poland, 1 with sites in Canada, 1 with sites in South Korea, 1 with sites in Australia, 1 with sites in Israel and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Enliven Therapeutics. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ELVN-001 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ELVN-001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ELVN-001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.